A Phase 1/2 interventional study of Eculizumab in Chronic Hemolysis, sponsored by Hadassah Medical Organization. Status unknown at 1 site in Israel. Open to participants aged 2 Months to 70 Years. Per ClinicalTrials.gov, last updated 2012-04-18.
Sponsored by Hadassah Medical Organization · Phase 1/2, Interventional, and Treatment
The investigators have identified patients with CD59 deficiency that suffers from chronic hemolysis and peripheral demyelinating disease. It was shown that complement terminal pathway can cause inflammation in the peripheral nervous system. Complement can greatly increase the immune attack in the nerves. Eculizumab has already been shown to be effective in a rare blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH). Attacks of PNH are also mediated through complement. Therefore, the investigators of this study are investigating whether by 'turning off' complement in CD59 deficiency, further attacks of hemolysis and nerve injury can be avoided and whether the neurological status will ameliorate.
It has been shown in some scientific studies that lack of CD59 in the context of the disease paroxysmal nocturnal hemoglobinuria (PNH)leads to chronic hemolysis. The investigators have identified patients wirh CD59 deficiency that suffers from chronic hemolysis and demyelinating disease. It was shown that complement terminal pathway can cause cause inflammation in nervous system. Complement can greatly increase the immune attack in the nerves. Eculizumab has already been shown to be effective in a rare blood disorder known as PNH. Attacks of PNH are also mediated through complement. Therefore, the investigators of this study are investigating whether by 'turning off' complement in CD59 deficiency, further attacks of hemolysis and nerve injury can be avoided.
The primary (most important) objectives of this study are to determine:
Whether Eculizumab ameliorate the neurological condition documented in the last month before treatment and whether it reduces the relapse frequency in patients with relapsing chronic inflammatory demyilinating polyneuropathy. The number of attacks during the one year treatment period will be compared to the number of attacks that occurred prior to initiation of eculizumab treatment. For patients with more than 2 year disease duration, the average number of attacks in the preceding 2 years will be calculated. For patients with less than 2 years disease duration the number of attacks in the preceding year will be used.
Whether Eculizumab reduces chronic hemolysis as judged by LDH levels, and haptoglobin, and level of hemoglobin. the same for corticosteroids and or I.V. IgG consumption before and after treatment with eculizumab.
The safety profile of eculizumab in patients with CD59 deficiency will be determined by parents report evry other week, documentation of clinic referral and hospitalizations. The number of participants with advers events will be determined.
The secondary objectives are to determine:
Whether eculizumab maintains or improves limbs motion, function and quality of life as measured by a variety of established disability scales like the modified SF36 and like a questionaire developed for this age group. The investigators will also assess the severity of an individual attack and the degree of recovery.
How the drug behaves in the patient's blood by measuring the presence of membrane attack complex on neutrophils and red blood cells.
184 studies on the registry are indexed under Hemolysis; 42 are open to participants now.
This study's planned enrollment of 5 is below the median of 36 across 113 interventional studies indexed under Hemolysis.
Browse Hemolysis studies →Hadassah Medical Organization is the lead sponsor of 659 studies on the registry; 54 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Eculizumab will be administrated according to known protocols.
Drug: Eculizumab
PNH and or atypical TTP classical protocols
Also known as: Soliris
Whether Eculizumab reduces chronic hemolysis
The primary objectives of this study are to determine: Whether Eculizumab reduces chronic hemolysis as judged by LDH levels, and haptoglobin, and level of hemoglobin.
Time frame: 8 months
Steroid and iv IgG cumulative dosage
Cumulative steroid and IgG dosage before and after treatment
Time frame: 8 months
Safety.
Whether the subjects develop known or possible related side effect to the treatment. The number of participants that develop adverse effects will be determined. reports from parents will be taken avery other week and documented clini or hospital visits will be included.
Time frame: 8 months
Whether Eculizumab ameliorates the neurological status compared to one month before treatment
The neurological status in the last month prior to treatment will be determined followed by neurological staus examination every two weeks.
Time frame: 8 months
Whether eculizumab maintains or improves limbs motion
Whether there is a neurological amelioration
Time frame: 8 months
function and quality of life as measured by a variety of established disability scales.
we will be using evry other week parents report of his clinical condition. We will use modified SF36 and local questionairre.
Time frame: 8 months
The severity of an individual attack and the degree of recovery.
Time frame: 8 months
Levels of membrane attack complex
This will be measured using flow cytometry for the presence of membrane attack complex on neutrophild and res blood cells.
Time frame: 8 months
This study is status unknown, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hadassah Medical Organization